Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.
Open accessThe DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Abstract
Pathological angiogenesis-driven by an imbalance of pro- and antiangiogenic signaling-is a hallmark of many diseases, both malignant and benign. Unlike in the healthy adult in which angiogenesis is tightly regulated, such diseases are characterized by uncontrolled new vessel formation, resulting in a microvascular network characterized by vessel immaturity, with profound structural and functional abnormalities. The consequence of these abnormalities is further modification of the microenvironment, often serving to fuel disease progression and attenuate response to conventional therapies. In this article, we present the "vascular normalization" hypothesis, which states that antiangiogenic therapy, by restoring the balance between pro- and antiangiogenic signaling, can induce a more structurally and functionally normal vasculature in a variety of diseases. We present the preclinical and clinical evidence supporting this concept and discuss how it has contributed to successful treatment of both solid tumors and several benign conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Antiangiogenic agents are thought to normalize tumor vasculature to allow for better delivery of chemotherapy.”
From Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma (2024) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“Intriguingly, however, the addition of anti-VEGF therapy to systemic chemotherapy has often proven to be an effective strategy, with patient outcomes superior to chemotherapy alone (Hurwitz et al. 2004; Sandler et al. 2006; Miller et al. 2007; Saltz et al. 2008; Reck et al. 2009).”
BackgroundTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187 · cited 2×
“…(VEGF) as the principal driver of tumor angiogenesis (Senger et al. 1983; Leung et al. 1989) rapidly prompted the development of antiangiogenic drugs to treat cancer, designed to inhibit VEGF’s activity and hence promote vascular regression and tumor starvation (Folkman 1971; Kim et al. 1993).”
BackgroundRanibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761 · cited 1×
“Intriguingly, however, the addition of anti-VEGF therapy to systemic chemotherapy has often proven to be an effective strategy, with patient outcomes superior to chemotherapy alone (Hurwitz et al. 2004; Sandler et al. 2006; Miller et al. 2007; Saltz et al. 2008; Reck et al. 2009).”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Self-citationMolecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Self-citationVascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986 · cited 2×
“The discovery of vascular endothelial growth factor (VEGF) as the principal driver of tumor angiogenesis (Senger et al. 1983; Leung et al. 1989) rapidly prompted the development of antiangiogenic drugs to treat cancer, designed to inhibit VEGF’s activity and hence promote vascular regression and tumor starvation (Folk…”
BackgroundTumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 1×
“Unlike physiological angiogenesis, blood vessel development in solid tumors is not tightly controlled, but rather occurs relentlessly (Dvorak 1986; Chung et al. 2010; Carmeliet and Jain 2011).”
BackgroundCancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Cited by
The biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?
Nakamura, Y., Mochida, A., Choyke, P. L., & Kobayashi, H. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00437 · Cited by 1,101
Defining normoxia, physoxia and hypoxia in tumours—implications for treatment response
McKeown, S. R. (2014) · The British Journal of Radiology · doi:10.1259/bjr.20130676 · Cited by 1,050
Pancreatic cancer stroma: an update on therapeutic targeting strategies
Hosein, A. N., Brekken, R. A., & Maitra, A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0300-1 · Cited by 950
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
Tian, L., Goldstein, A., Wang, H., Ching Lo, H., Sun Kim, I., Welte, T., Sheng, K., Dobrolecki, L. E., Zhang, X., Putluri, N., et al. (2017) · Nature · doi:10.1038/nature21724 · Cited by 841
The Role of Angiogenesis in Cancer Treatment
Rajabi, M., & Mousa, S. (2017) · Biomedicines · doi:10.3390/biomedicines5020034 · Cited by 656
“Jain reported that for both direct or indirect antiangiogenic therapy, the balance between pro-angiogenic and anti-angiogenic factors will be restored through the reduction of vessel permeability and hypoxia and enhancement of the homogeneity of blood flow and perivascular cells coverage [82].”
BackgroundRecent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
Welti, J., Loges, S., Dimmeler, S., & Carmeliet, P. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70212 · Cited by 591
“Mode of action is incompletely understood (5, 109, 132) Preclinical research to understand vessel-normalizing (4, 45, 160, 161) versus vessel-regressing (111) effects; analyze effects on cancer stem cells (92)”
The Extracellular Matrix Modulates the Metastatic Journey
Kai, F., Drain, A. P., & Weaver, V. M. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.03.026 · Cited by 537
“To address these issues vascular normalization has been proposed as a therapeutic strategy aimed at reducing mechanical stresses in the tumor stroma and ultimately preventing metastasis (Goel et al., 2012).”
BackgroundImproving drug delivery to solid tumors: Priming the tumor microenvironment
Khawar, I. A., Kim, J. H., & Kuh, H.-J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.018 · Cited by 533
An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
Palazon, A., Tyrakis, P. A., Macias, D., Veliça, P., Rundqvist, H., Fitzpatrick, S., Vojnovic, N., Phan, A. T., Loman, N., Hedenfalk, I., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.003 · Cited by 521
“Tumor response to chemotherapy is known to be affected by the levels of oxygenation and the ability of the vessel network to deliver drugs (Goel et al., 2012).”
BackgroundEl-Sawy, H. S., Al-Abd, A. M., Ahmed, T. A., El-Say, K. M., & Torchilin, V. P. (2018) · ACS Nano · doi:10.1021/acsnano.8b06104 · Cited by 431
YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma
Hou, J., Zhang, H., Liu, J., Zhao, Z., Wang, J., Lu, Z., Hu, B., Zhou, J., Zhao, Z., Feng, M., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1082-3 · Cited by 361
Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer
Enriquez-Navas, P. M., Kam, Y., Das, T., Hassan, S., Silva, A., Foroutan, P., Ruiz, E., Martinez, G., Minton, S., Gillies, R. J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7842 · Cited by 322
The angiogenic properties of mesenchymal stem/stromal cells and their therapeutic potential
Watt, S. M., Gullo, F., van der Garde, M., Markeson, D., Camicia, R., Khoo, C. P., & Zwaginga, J. J. (2013) · British Medical Bulletin · doi:10.1093/bmb/ldt031 · Cited by 273
KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis
Murgai, M., Ju, W., Eason, M., Kline, J., Beury, D. W., Kaczanowska, S., Miettinen, M. M., Kruhlak, M., Lei, H., Shern, J. F., et al. (2017) · Nature Medicine · doi:10.1038/nm.4400 · Cited by 263
Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases
Fallah, A., Sadeghinia, A., Kahroba, H., Samadi, A., Heidari, H. R., Bradaran, B., Zeinali, S., & Molavi, O. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.022 · Cited by 259
Ojha, T., Pathak, V., Shi, Y., Hennink, W. E., Moonen, C. T. W., Storm, G., Kiessling, F., & Lammers, T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.007 · Cited by 260
Dong, X., Liu, H.-J., Feng, H.-Y., Yang, S.-C., Liu, X.-L., Lai, X., Lu, Q., Lovell, J. F., Chen, H.-Z., & Fang, C. (2019) · Nano Letters · doi:10.1021/acs.nanolett.8b04236 · Cited by 223
Nutrigenomics of extra‐virgin olive oil: A review
Piroddi, M., Albini, A., Fabiani, R., Giovannelli, L., Luceri, C., Natella, F., Rosignoli, P., Rossi, T., Taticchi, A., Servili, M., et al. (2017) · BioFactors · doi:10.1002/biof.1318 · Cited by 196
“That response decreased leading to inhibition vascular injury and the hemodynamic alteration of tumors (vascular normalization hypothesis [187]).”
BackgroundUnderstanding tumour endothelial cell heterogeneity and function from single-cell omics
Zeng, Q., Mousa, M., Nadukkandy, A. S., Franssens, L., Alnaqbi, H., Alshamsi, F. Y., Safar, H. A., & Carmeliet, P. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00591-5 · Cited by 194
Modulating tumor hypoxia by nanomedicine for effective cancer therapy
Jahanban‐Esfahlan, R., de la Guardia, M., Ahmadi, D., & Yousefi, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.25859 · Cited by 201
Plaque angiogenesis and intraplaque hemorrhage in atherosclerosis
Parma, L., Baganha, F., Quax, P. H. A., & de Vries, M. R. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.04.028 · Cited by 181
“Ang-1 together with platelet derived growth factor (PDGF) acts as a major stabilizing factor that increases the stability of the junctions between the EC, thus promoting vessel maturity and stability and reducing leakiness (Goel et al., 2012).”
BackgroundInfluentialUltrasound-mediated nano drug delivery for treating cancer: Fundamental physics to future directions
Moradi Kashkooli, F., Jakhmola, A., Hornsby, T. K., Tavakkoli, J. (., & Kolios, M. C. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.009 · Cited by 177
Pathological angiogenesis and inflammation in tissues
Jeong, J.-H., Ojha, U., & Lee, Y. M. (2021) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01287-2 · Cited by 174
Targeted modulation of immune cells and tissues using engineered biomaterials
Yousefpour, P., Ni, K., & Irvine, D. J. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-022-00016-2 · Cited by 164
Tang, J., Li, Z., Lu, L., & Cho, C. H. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.08.009 · Cited by 160
A systems biology view of blood vessel growth and remodelling
Logsdon, E. A., Finley, S. D., Popel, A. S., & Gabhann, F. M. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12164 · Cited by 187
“The DATIA model also allows for the investigation of vessel normalization, whereby tumour vasculature morphology changes to more closely resemble normal vessels [40,41].”
BackgroundCircadian rhythms and cancers: the intrinsic links and therapeutic potentials
Zhou, L., Zhang, Z., Nice, E. C., Huang, C., Zhang, W., & Tang, Y. C. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01238-y · Cited by 177
Patel, A., Sabbineni, H., Clarke, A., & Somanath, P. R. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.05.036 · Cited by 156
“Angiogenesis, a tightly regulated process is triggered by stimuli such as hypoxia, acidosis, growth factors, oncogenic signaling, hormones, cytokines [132-135] and is necessary to meet the demands of normal cell or solid tumors.”
BackgroundYang, L., & Lin, P. C. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.001 · Cited by 155
Adapala, R. K., Thoppil, R. J., Ghosh, K., Cappelli, H. C., Dudley, A. C., Paruchuri, S., Keshamouni, V, Klagsbrun, M., Meszaros, J. G., Chilian, W. M., et al. (2016) · Oncogene · doi:10.1038/onc.2015.83 · Cited by 153
Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy
Sápi, J., Kovács, L., Drexler, D. A., Kocsis, P., Gajári, D., & Sápi, Z. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142190 · Cited by 156
Releasing Pressure in Tumors: What Do We Know So Far and Where Do We Go from Here? A Review
Ariffin, A. B., Forde, P. F., Jahangeer, S., Soden, D. M., & Hinchion, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3696 · Cited by 150
Norton, K., & Popel, A. S. (2016) · Scientific Reports · doi:10.1038/srep36992 · Cited by 163
Hyperthermia can alter tumor physiology and improve chemo- and radio-therapy efficacy
Dunne, M., Regenold, M., & Allen, C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.007 · Cited by 150
Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy
Moosavian, S. A., Bianconi, V., Pirro, M., & Sahebkar, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.025 · Cited by 156
Exercise as adjunct therapy in cancer
Ashcraft, K. A., Warner, A. B., Jones, L. W., & Dewhirst, M. W. (2019) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2018.10.001 · Cited by 148
The Warburg Effect in Endothelial Cells and its Potential as an Anti-angiogenic Target in Cancer
Fitzgerald, G., Soro-Arnáiz, I., & Bock, K. D. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00100 · Cited by 145
“Pro-angiogenic factors are indicated in red and anti-angiogenic factors are indicated in green. sprouting (Guarani et al., 2011).”
BackgroundLeung, C. S., Yeung, T.-L., Yip, K.-P., Wong, K.-K., Ho, S. Y., Mangala, L. S., Sood, A. K., Lopez-Berestein, G., Sheng, J., Wong, S. T. C., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci95200 · Cited by 132
Normalizing Tumor Vasculature to Reduce Hypoxia, Enhance Perfusion, and Optimize Therapy Uptake
Matuszewska, K., Pereira, M., Petrik, D., Lawler, J., & Petrik, J. (2021) · Cancers · doi:10.3390/cancers13174444 · Cited by 134
Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy
Dvorak, H. F. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000124 · Cited by 116
Targeting VEGF pathway to normalize the vasculature: an emerging insight in cancer therapy
Wu, J., Tang, Y., & Liang, X. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s172042 · Cited by 105
Pak, R. W., Hadjiabadi, D. H., Senarathna, J., Agarwal, S., Thakor, N. V., Pillai, J. J., & Pathak, A. P. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17707398 · Cited by 118
Real-time monitoring of drug pharmacokinetics within tumor tissue in live animals
Seo, J.-W., Fu, K. X., Correa, S., Eisenstein, M. S., Appel, E. A., & Soh, H. T. (2022) · Science Advances · doi:10.1126/sciadv.abk2901 · Cited by 110
Photodynamic Therapy and the Biophysics of the Tumor Microenvironment
Sorrin, A. J., Ruhi, M. K., Ferlic, N. A., Karimnia, V., Polacheck, W. J., Celli, J. P., Huang, H., & Rizvi, I. (2020) · Photochemistry and Photobiology · doi:10.1111/php.13209 · Cited by 109
Mondini, M., Nizard, M., Tran, T., Mauge, L., Loi, M., Clémenson, C., Dugué, D., Maroun, P., Louvet, E., Adam, J., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1015 · Cited by 104
“Vascular normalization has been proposed to be a key mechanism in mediating antitumor responses (33, 34), enhancing cancer immunotherapy (16, 35).”
Gordon-Weeks, A. N., Lim, S. Y., Yuzhalin, A. E., Lucotti, S., Vermeer, J. A. F., Jones, K. I., Chen, J., & Muschel, R. J. (2019) · Cancers · doi:10.3390/cancers11050630 · Cited by 97
“This may be because we analysed liver metastases at the terminal phase of their growth and that LAMA5 inhibition in fact causes vessel normalisation with a transient increase in perfusion, as is seen for the vascular normalising effects of VEGF inhibition [38].”
BackgroundGaspar, N., Venkatramani, R., Hecker-Nolting, S., Melcon, S. G., Locatelli, F., Bautista, F., Longhi, A., Lervat, C., Entz-Werle, N., Casanova, M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00387-9 · Cited by 89
Anti-angiogenesis in cancer therapeutics: the magic bullet
Oguntade, A. S., Al-Amodi, F., Alrumayh, A., Alobaida, M., & Bwalya, M. (2021) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-021-00072-6 · Cited by 99
Tumor Vessels Fuel the Fire in Glioblastoma
Rosińska, S., & Gavard, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126514 · Cited by 91
Endothelial YAP/TAZ Signaling in Angiogenesis and Tumor Vasculature
Hooglugt, A., van der Stoel, M. M., Boon, R. A., & Huveneers, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.612802 · Cited by 82
M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma
Jarosz–Biej, M., Kamińska, N., Matuszczak, S., Cichoń, T., Pamuła‐Piłat, J., Czapla, J., Smolarczyk, R., Skwarzyńska, D., Kulik, K., & Szala, S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191012 · Cited by 89
Rodenhizer, D., Dean, T., D'Arcangelo, E., & McGuigan, A. P. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701174 · Cited by 80
Cancer drug resistance: A fleet to conquer
Hussain, S., Singh, A., Nazir, S. U., Tulsyan, S., Khan, A., Kumar, R., Bashir, N., Tanwar, P., & Mehrotra, R. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28782 · Cited by 86
Molecular Regulation of Sprouting Angiogenesis
Duran, C. L., Howell, D. W., Dave, J. M., Smith, R. L., Torrie, M. E., Essner, J. J., & Bayless, K. J. (2017) · Comprehensive physiology · doi:10.1002/cphy.c160048 · Cited by 86
Li, W., Li, X., Liu, S., Yang, W., Pan, F., Yang, X.-Y., Du, B., Qin, L., & Pan, Y. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s128802 · Cited by 77
Yeung, T.-L., Leung, C. S., Yip, K., Sheng, J., Vien, L., Bover, L. C., Birrer, M. J., Wong, S. T. C., & Mok, S. C. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0187 · Cited by 81
“org Clin Cancer Res; 25(21) November 1, 2019 6425”
BackgroundInfluentialCheng, N., Bei, Y., Song, Y., Zhang, W., Xu, L., Zhang, W., Yang, N., Bai, X., Shu, Y., & Shen, P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114298 · Cited by 73
Control of cancer formation by intrinsic genetic noise and microenvironmental cues
Brock, A., Krause, S., & Ingber, D. E. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3959 · Cited by 74
Qin, T., Wang, C., Chen, X., Duan, C., Zhang, X., Zhang, J., Chai, H., Tang, T., Chen, H., Yue, J., et al. (2015) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.03.021 · Cited by 76
The lymphatic system and pancreatic cancer
Fink, D. M., Steele, M. M., & Hollingsworth, M. A. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.11.048 · Cited by 77
“These findings led to the evolution of the current vascular normalization theory: the use of anti-angiogenic therapy to block aberrant tumor angiogenesis and alleviate vessel dysfunction [349].”
BackgroundTumor Microenvironment on a Chip: The Progress and Future Perspective
Ahn, J., Sei, Y., Jeon, N., & Kim, Y. (2017) · Bioengineering · doi:10.3390/bioengineering4030064 · Cited by 69
“Several animal models have been used to investigate the EPR effect [81], solid tumor stress [105] and normalization of tumor blood vessels [115].”
BackgroundTorok, S., Rezeli, M., Kelemen, O., Vegvari, A., Watanabe, K., Sugihara, Y., Tisza, A., Marton, T., Kovacs, I., Tovari, J., et al. (2017) · Theranostics · doi:10.7150/thno.16767 · Cited by 70
“Of note, this is in contrast to the "vessel normalization theory" proposed by Jain and colleagues whereby treatment with an antiangiogenic agent such as bevacizumab [45] normalizes the chaotic tumor blood vessel network thus increasing chemotherapeutic drug delivery.”
ResultAngiogenesis in melanoma: an update with a focus on current targeted therapies
Jour, G., Ivan, D. S., & Aung, P. P. (2016) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-203482 · Cited by 75
Pharmacokinetic strategies to improve drug penetration and entrapment within solid tumors
Al-Abd, A. M., Aljehani, Z. K., Gazzaz, R. W., Fakhri, S. H., Jabbad, A. H., Alahdal, A. M., & Torchilin, V. P. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.055 · Cited by 69
Improving cancer treatments via dynamical biophysical models
Kuznetsov, M. B., Clairambault, J., & Volpert, V. A. (2021) · Physics of Life Reviews · doi:10.1016/j.plrev.2021.10.001 · Cited by 71
Endothelial deficiency of L1 reduces tumor angiogenesis and promotes vessel normalization
Magrini, E. I., Villa, A., Angiolini, F., Doni, A., Mazzarol, G., Rudini, N., Maddaluno, L., Komuta, M., Topal, B., Prenen, H., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70683 · Cited by 64
“Third, the observation that L1 destabilizes cancer-associated vessels implies that targeting endothelial L1 and interfering with its function might result in vessel normalization, a process that has been proposed to improve the delivery into the tumor of systemically administered chemotherapeutics (4).”
InfluentialWhom to blame for metastasis, the epithelial–mesenchymal transition or the tumor microenvironment?
Pietilä, M., Ivaska, J., & Mani, S. A. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.12.033 · Cited by 69
“proaches aimed at “vascular normalization” to reduce microvascular permeability and inhibit tumor progression have been suggested as a potential anti-tumor strategy [59].”
BackgroundTumor priming using metronomic chemotherapy with neovasculature-targeted, nanoparticulate paclitaxel
Luan, X., Guan, Y., Lovell, J. F., Zhao, M., Lu, Q., Liu, Y., Liu, H.-J., Gao, Y., Dong, X., Yang, S., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.04.008 · Cited by 65
Li, W., Quan, Y.-Y., Li, Y., Lu, L., & Cui, M. (2018) · Cancer Management and Research · doi:10.2147/cmar.s174712 · Cited by 61
Vähätupa, M., Järvinen, T. A. H., & Uusitalo‐Järvinen, H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00873 · Cited by 63
Fu, R., Li, Y., Jiang, N., Ren, B., Zang, C.-Z., Liu, L., Lv, W., Li, H., Weiss, S. J., Li, Z., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131507 · Cited by 64
Tsuji‐Tamura, K., & Ogawa, M. (2016) · Journal of Cell Science · doi:10.1242/jcs.178434 · Cited by 63
“Formation of functional and stable vessels can improve the delivery of antitumor drugs into tumor cells (Carmeliet and Jain, 2011; Goel et al., 2012).”
BackgroundTumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery
Kim, S. J., Jung, K. H., Son, M. K., Park, J. H., YAN, H. H., Fang, Z., Kang, Y. W., Han, B., Lim, J. H., & Hong, S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.035 · Cited by 61
Smith, B. R., Zavaleta, C. L., Rosenberg, J., Tong, R. T., Ramunas, J., Liu, Z., Dai, H., & Gambhir, S. S. (2013) · Nano Today · doi:10.1016/j.nantod.2013.02.004 · Cited by 57
Effects of Anti-Angiogenesis on Glioblastoma Growth and Migration: Model to Clinical Predictions
Scribner, E. Y., Saut, O., Province, P., Bag, A. K., Colin, T., & Fathallah‐Shaykh, H. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115018 · Cited by 58
“The Jain vascular normalization hypothesis stipulates that anti-angiogenic therapy could induce a transient normalization of the structure and function of some blood vessels in the tumor by improving vascular permeability, organization, and perfusion [32].”
InfluentialWang, Z., Kerketta, R., Chuang, Y.-L., Dogra, P., Butner, J. D., Brocato, T. A., Day, A., Xu, R., Shen, H., Simbawa, E. A., et al. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004969 · Cited by 61
“, theories such as Transport Oncophysics and vascular normalization) [2, 3], and are supported by experimental data in animal cancer models and cancer patients [4, 5].”
BackgroundDocetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression
Harris, A. R., Perez, M. J., & Munson, J. M. (2018) · BMC Cancer · doi:10.1186/s12885-018-4619-8 · Cited by 60
“Normalization of vasculature in cancer has been an area of therapeutic interest for many years [73].”
BackgroundDavis, G. E., Norden, P. R., & Bowers, S. (2015) · Connective Tissue Research · doi:10.3109/03008207.2015.1066781 · Cited by 58
APOPTOSIS IN RADIATION THERAPY: A DOUBLE-EDGED SWORD
Greenebaum, S. (2012) · Cited by 56
Inhibition of nuclear Wnt signalling: challenges of an elusive target for cancer therapy
Lyou, Y., Habowski, A. N., Chen, G. T., & Waterman, M. L. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13963 · Cited by 58
“This process has been successfully targeted leading to the development of multiple anti-angiogenesis agents that are FDA approved and widely used in the clinic (Goel et al., 2012; Jain, 2014).”
BackgroundTadeo, I., Berbegall, A. P., Castel, V., García‐Miguel, P., Callaghan, R. C., Påhlman, S., Navarro, S., & Noguera, R. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.210 · Cited by 57
“This normalised tumour vasculature becomes less permeable and tortuous with their normal function restored (Jain et al, 2007; Goel et al, 2012).”
BackgroundSilwal‐Pandit, L., Nord, S., Gythfeldt, H. V. D. L., Møller, E. K., Fleischer, T., Rødland, E. A., Krohn, M., Borgen, E., Garred, Ø., Olsen, T., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0160 · Cited by 59
“Blocking VEGF by bevacizumab, anmAb, has been proposed to cause inhibition of neovascularization, regression of existing immature microvessels, and normalization of abnormal vasculature (4, 5); this has consequences for the flux of oxygen, nutrients, metabolites, and therapeutic agents, ultimately preventing tumor gro…”
BackgroundErk5 inhibits endothelial migration via KLF2-dependent down-regulation of PAK1
Komaravolu, R. K., Adam, C., Moonen, J.-R. A. J., Harmsen, M. C., Goebeler, M., & Schmidt, M. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu236 · Cited by 58
“However, enhanced endothelial migration and angiogenesis is also a hallmark of cancer and contributes to the pathogenesis of vascular diseases including atherosclerosis.(4,5) In the latter, enhanced endothelial migration and angiogenesis, for instance, is closely associated with intraplaque haemorrhage, a proposed ris…”
Apoptosis in radiation therapy: a double-edged sword.
Balcer‐Kubiczek, E. K. (2012) · PubMed · Cited by 78
Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model
Beedie, S., Mahony, C. B., Walker, H. M., Chau, C. H., Figg, W. D., & Vargesson, N. (2016) · Scientific Reports · doi:10.1038/srep30038 · Cited by 57
Modelling the transport of fluid through heterogeneous, whole tumours in silico
Sweeney, P. W., d’Esposito, A., Walker‐Samuel, S., & Shipley, R. J. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006751 · Cited by 54
Yang, Y., Xu, W., Peng, D., Wang, H., Zhang, X., Wang, H., Xiao, F., Zhu, Y., Ji, Y., Gulukota, K., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.059 · Cited by 54
“sT-mediated downregulation of VEGFA and VEGFR can also inhibit angiogenesis, and thus can also directly affect tumor growth.(44) Our results also suggest that the intratumoral administration of rAd.”
Class 3 semaphorins: physiological vascular normalizing agents for anti‐cancer therapy
Serini, G., Bussolino, F., Maione, F., & Giraudo, E. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12017 · Cited by 50
Yamamoto, S., Kato, A., Sakurai, Y., Hada, T., & Harashima, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.02.010 · Cited by 46
“This improvement by inhibiting VEGF signaling in the therapeutic effects of lowmolecularweight compounds can be attributed to a recovery of blood flow, the inhibition of leakage in outer areas of the tumor tissue via lowered permeability and a decrease in interstitial fluid pressure (IFP) [16].”
BackgroundDendritic cell vaccine therapy for colorectal cancer
Wooster, A. L., Girgis, L. H., Brazeale, H., Anderson, T. S., Wood, L. M., & Lowe, D. B. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105374 · Cited by 48
Adjuvant Novel Nanocarrier-Based Targeted Therapy for Lung Cancer
Sarma, K., Akhter, M. H., Ahmad, I. S., Afzal, O., Altamimi, A. S. A., Alossaimi, M. A., Jaremko, M., Emwas, A.-H. M., & Gautam, P. (2024) · Molecules · doi:10.3390/molecules29051076 · Cited by 48
Zhang, S., Deshpande, A. M., Verma, B. K., Wang, H., Mi, H., Yuan, L., Ho, W. J., Jaffee, E. M., Zhu, Q., Anders, R. A., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0943 · Cited by 53
The biological roles and clinical implications of microRNAs in clear cell renal cell carcinoma
He, Y., Chen, C., & Shi, Z. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26347 · Cited by 48
“The vascular endothelial growth factor (VEGF) plays a vital role in regulating the process of angiogenesis, and the clinical effect from targeting this system in metastaticrenal cell carcinoma patients is well performed(Goel et al., 2012).”
BackgroundYonucu, S., Yιlmaz, D., Phipps, C., Unlu, M. B., & Kohandel, M. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005724 · Cited by 46
Tao, L., Huang, G., Shi, S., & Chen, L. (2013) · Medical Oncology · doi:10.1007/s12032-013-0777-3 · Cited by 47
Tumor vasculature remolding by thalidomide increases delivery and efficacy of cisplatin
Shen, Y., Li, S., Wang, X., Wang, M., Tian, Q., Yang, J., Wang, B., Wang, B., Liu, P., & Yang, J. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1366-x · Cited by 51
Metadata
- Authors
- Goel, S., Wong, A. H.-K., & Jain, R. K.
- Affiliations
- Harvard University (US)
- ORCID
- Goel, S.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2011-10-18
- Volume
- 2
- Issue
- 3
- Pages
- a006486-a006486
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC3282493
- OpenAlex
- W2115852392
- Cited by
- 352
- References
- 191
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 22 · 2023: 27 · 2022: 18 · 2021: 31 · 2020: 30 · 2019: 23 · 2018: 30 · 2017: 38 · 2016: 29 · 2015: 28 · 2014: 21 · 2013: 13 · 2012: 5
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense (W81XWH1010016, W81XWH)
- US-UK Fulbright Commission
- Fulbright Australia
- National Institutes of Health (W81XWH, CA126642, CA115767, R01-CA85140)
- National Cancer Institute (R01CA115767, W81XWH-10-1-0016, R01 CA 85140, R01CA085140, P01CA080124, R01CA126642, P01-CA-80124)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- vascular normalization, pathological angiogenesis, anti-angiogenic therapy, tumor vasculature, tumor microenvironment, solid tumors
- MeSH terms
- Cytotoxins, Humans, Macular Degeneration, Neoplasms, Neuroma, Acoustic, Psoriasis, Telangiectasia, Hereditary Hemorrhagic, Disease Progression, Neovascularization, Physiologic, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Angiopoietin-2, Microvessels, Plaque, Atherosclerotic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.